Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):1997–2002. doi: 10.1128/aac.38.9.1997

Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture.

J M Colacino 1, S K Malcolm 1, S R Jaskunas 1
PMCID: PMC284674  PMID: 7811009

Abstract

Fialuridine (FIAU) is a nucleoside analog with potent activity against hepatitis B virus in vitro and in vivo. In this report, the effect of FIAU on mitochondrial DNA (mtDNA) replication in vitro was investigated. CEM cells, a cell line derived from human T cells, were incubated for 6 days in up to 20 microM FIAU. Total cellular DNA was isolated, normalized for the number of cells, and slot hybridized to a probe specific for mtDNA sequences. Treatment of CEM cells with FIAU did not result in a dose-dependent decrease in the amount of mtDNA. In contrast, dideoxycytidine (ddC) inhibited mtDNA replication by 50% at a concentration of approximately 0.1 microM. After 6 days of incubation, both compounds displayed a 50% toxic dose at a concentration of approximately 2 microM in CEM cells and approximately 34 microM in human hepatoblastoma cells (HepG2). In further experiments, CEM cells were incubated for 15 days in up to 2.5 microM FIAU, and again, no inhibition of mtDNA was observed. Over a 6-day incubation, FIAU, at concentrations of up to 200 microM, also failed to inhibit mtDNA replication in either HepG2 or HepG2 cells which constitutively replicate duck hepatitis B virus. In contrast, ddC inhibited mtDNA replication in these cells with a 50% inhibitory concentration of approximately 0.2 microM over a 6-day incubation. Treatment of cells with either FIAU or ddC resulted in a dose-dependent increase in lactate levels in the cell medium, indicating that any effect of FIAU on mitochondrial function may not be related to inhibition of mtDNA replication on the basis of the in vitro data. Alternative explanations for mitochondrial toxicity are considered.

Full text

PDF
1997

Images in this article

1998Image
on p.1998
1999Image
on p.1999
1999Image
on p.1999
1999Image
on p.1999

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaudo E., Dalakas M., Shanske S., Moraes C. T., DiMauro S., Schon E. A. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991 Mar 2;337(8740):508–510. doi: 10.1016/0140-6736(91)91294-5. [DOI] [PubMed] [Google Scholar]
  2. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  3. Chen C. H., Cheng Y. C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. J Biol Chem. 1992 Feb 15;267(5):2856–2859. [PubMed] [Google Scholar]
  4. Chen C. H., Vazquez-Padua M., Cheng Y. C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991 May;39(5):625–628. [PubMed] [Google Scholar]
  5. Chen M. S., Van Nostrand M., Oshana S. C. Quantitative determination of antiviral nucleoside analog in DNA. Anal Biochem. 1986 Aug 1;156(2):300–304. doi: 10.1016/0003-2697(86)90256-3. [DOI] [PubMed] [Google Scholar]
  6. Cheng Y. C., Dutschman G., Fox J. J., Watanabe K. A., Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981 Sep;20(3):420–423. doi: 10.1128/aac.20.3.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dalakas M. C., Illa I., Pezeshkpour G. H., Laukaitis J. P., Cohen B., Griffin J. L. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990 Apr 19;322(16):1098–1105. doi: 10.1056/NEJM199004193221602. [DOI] [PubMed] [Google Scholar]
  8. Dubinsky R. M., Yarchoan R., Dalakas M., Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve. 1989 Oct;12(10):856–860. doi: 10.1002/mus.880121012. [DOI] [PubMed] [Google Scholar]
  9. Galle P. R., Schlicht H. J., Fischer M., Schaller H. Production of infectious duck hepatitis B virus in a human hepatoma cell line. J Virol. 1988 May;62(5):1736–1740. doi: 10.1128/jvi.62.5.1736-1740.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gertner E., Thurn J. R., Williams D. N., Simpson M., Balfour H. H., Jr, Rhame F., Henry K. Zidovudine-associated myopathy. Am J Med. 1989 Jun;86(6 Pt 2):814–818. doi: 10.1016/0002-9343(89)90478-6. [DOI] [PubMed] [Google Scholar]
  11. Grant A. J., Feinberg A., Chou T. C., Watanabe K. A., Fox J. J., Philips F. S. Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol. 1982 Mar 15;31(6):1103–1108. doi: 10.1016/0006-2952(82)90349-5. [DOI] [PubMed] [Google Scholar]
  12. Korba B. E., Gerin J. L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 1992 Jul 1;19(1):55–70. doi: 10.1016/0166-3542(92)90056-b. [DOI] [PubMed] [Google Scholar]
  13. Lamperth L., Dalakas M. C., Dagani F., Anderson J., Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest. 1991 Dec;65(6):742–751. [PubMed] [Google Scholar]
  14. Lewis W., Gonzalez B., Chomyn A., Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest. 1992 Apr;89(4):1354–1360. doi: 10.1172/JCI115722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lewis W., Papoian T., Gonzalez B., Louie H., Kelly D. P., Payne R. M., Grody W. W. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest. 1991 Aug;65(2):228–236. [PubMed] [Google Scholar]
  16. Lewis W., Simpson J. F., Meyer R. R. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res. 1994 Feb;74(2):344–348. doi: 10.1161/01.res.74.2.344. [DOI] [PubMed] [Google Scholar]
  17. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Masters J. N., Finch C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron. 1990 Dec;5(6):831–839. doi: 10.1016/0896-6273(90)90342-d. [DOI] [PubMed] [Google Scholar]
  18. Mhiri C., Baudrimont M., Bonne G., Geny C., Degoul F., Marsac C., Roullet E., Gherardi R. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol. 1991 Jun;29(6):606–614. doi: 10.1002/ana.410290607. [DOI] [PubMed] [Google Scholar]
  19. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  20. Staschke K. A., Colacino J. M., Mabry T. E., Jones C. D. The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994 Jan;23(1):45–61. doi: 10.1016/0166-3542(94)90032-9. [DOI] [PubMed] [Google Scholar]
  21. Weislow O. S., Kiser R., Fine D. L., Bader J., Shoemaker R. H., Boyd M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst. 1989 Apr 19;81(8):577–586. doi: 10.1093/jnci/81.8.577. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES